Why collect individual-level vaccination data?

Kwong, Jeffrey C.
February 2010
CMAJ: Canadian Medical Association Journal;2/23/2010, Vol. 182 Issue 3, p273
Academic Journal
The article presents a reprint of the article "Why collect individual-level vaccination data?" that appeared at www.cmaj.ca. It discusses the importance of collecting individual-level vaccination data in Canada. It stresses that individual-level vaccination data are critical for the timely evaluation of vaccine coverage, effectiveness and safety at the population level.


Related Articles

  • In the mood for wiping out vaccine-preventable diseases. Fleck, Fiona // Bulletin of the World Health Organization;Apr2014, Vol. 92 Issue 4, p236 

    An interview with executive vice president of the Sabin Vaccine Institute, Ciro de Quadros, is presented. He discusses how he became interested in immunization while involved with a smallpox programme in Brazil in 1969, what disease surveillance and containment is and how he helped to develop...

  • Recommended Adult Immunization Schedule -- United States, October 2005--September 2006.  // MMWR: Morbidity & Mortality Weekly Report;10/14/2005, Vol. 54 Issue 40, pQ-1 

    Focuses on the recommended Adult Immunization Schedule in the U.S. for October 2005 to September 2006. Difference of the 2005-2006 schedule from the previous schedule; Recommended dose of tetanus diphtheria vaccine for people aged 50-64 years; Web sites to access for further information on...

  • Do Vaccines Save Lives? Yes They Do! LERNOUT, Tinne; THEETEN, Heidi; LEURIDAN, Elke; VAN DAMME, Pierre // Acta Medica Portuguesa;mar/abr2014, Vol. 27 Issue 2, p160 

    Since their introduction and widespread use, vaccines have been very successful in reducing morbidity and mortality of the diseases they target, at an individual level and through herd immunity. The impact on the mortality has been rapid and easy to measure for some diseases, such as diphtheria,...

  • Vaccine development strategies for improving immunization: the role of modern immunology. Levine, Myron M.; Sztein, Marcelo B. // Nature Immunology;May2004, Vol. 5 Issue 5, p460 

    An ideal vaccine has certain biological and physical characteristics. Technological advances have provided new strategies that may help the design of such a vaccine.

  • A Prospective Study of the Effectiveness of the New Zealand Meningococcal B Vaccine. Colleen Kelly; Richard Arnold; Yvonne Galloway; Jane OHallahan // American Journal of Epidemiology;Oct2007, Vol. 166 Issue 7, p817 

    The effectiveness of a new group B strain-specific meningococcal vaccine referred to as “MeNZB,” developed by Chiron Vaccines (Siena, Italy) in collaboration with the Norwegian Institute of Public Health, was assessed in a prospective observational study following a...

  • Acute viscerotropic disease following vaccination against yellow fever. Hayes, Edward B. // Transactions of the Royal Society of Tropical Medicine & Hygiene;Oct2007, Vol. 101 Issue 10, p967 

    Summary: Acute viscerotropic disease following yellow fever vaccination (YEL-AVD) is a rare but serious complication of vaccination with 17D yellow fever vaccine. This paper reviews the existing literature regarding YEL-AVD and discusses possible etiologic mechanisms. A greater understanding of...

  • Vaccine Effectiveness Estimates, 2004-2005 Mumps Outbreak, England. Cohen, Cheryl; White, Joanne M.; Savage, Emma J.; Glynn, Judith R.; Yoon Choi; Andrews, Nick; Brown, David; Ramsay, Mary E. // Emerging Infectious Diseases;Jan2007, Vol. 13 Issue 1, p12 

    The United Kingdom and United States have recently experienced large outbreaks of mumps, which raises concerns about vaccine effectiveness. The effectiveness of the mumps component of the measles, mumps, rubella (MMR) vaccine was estimated using the screening method. In England from January 2004...

  • Successful Booster Antibody Response up to 54 Months after Single Primary Vaccination with Virosome-Formulated, Aluminum-Free Hepatitis A Vaccine. Beck, Bernhard R.; Hatz, Christoph; Brönnimann, Rainer; Herzog, Christian // Clinical Infectious Diseases;11/1/2003, Vol. 37 Issue 9, p126 

    This study demonstrates that a booster dose of the virosome-formulated, aluminum-free hepatitis A vaccine Epaxal (Berna Biotech) is highly immunogenic in subjects who received a single primary dose of this vaccine 18–54 months earlier. There were no significant differences in geometric...

  • Two at a Time.  // Pediatrics for Parents;May/Jun2012, Vol. 28 Issue 5/6, p1 

    The article discusses a study which found that multiple vaccinations given to children at the same time do not have an impact on the ability of children to develop immunity to illnesses.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics